Berenberg Issues a Downgrade for MorphoSys (MOR) from a Buy to Hold Rating

September 8, 2018 - By Mary Kidd

MorphoSys (MOR) Receives a Downgrade

The Rating of MorphoSys (MOR) shares have been downgraded by Berenberg from a Buy rating to a Hold rating in a research report shared with investors and clients on 7 September.

The stock increased 0.55% or $0.15 during the last trading session, reaching $27.41. About 93,060 shares traded or 70.17% up from the average. MorphoSys AG (MOR) has 0.00% since September 8, 2017 and is . It has underperformed by 12.57% the S&P500.

MorphoSys AG, together with its subsidiaries, engages in the research, development, and optimization of therapeutic antibody drug candidates in partnership with pharmaceutical and biotechnology companies. The company has market cap of $3.54 billion. The company, together with its pharmaceutical partners, develops a therapeutic pipeline of approximately 100 drugs for the treatment of cancer, Alzheimer's disease, infectious diseases, cardiovascular dysfunction, and inflammation. It currently has negative earnings. The Company’s product pipeline includes MOR208, a humanized monoclonal antibody that targets the antigen CD19, which is in Phase III clinical trial for the treatment of B cell malignancies; and MOR202, a human monoclonal HuCAL antibody directed against CD38, which is in Phase II trial for the treatment of multiple myeloma and other cancers.

More recent MorphoSys AG (NASDAQ:MOR) news were published by: Streetinsider.com which released: “Form 6-K MorphoSys AG For: Sep 06” on September 06, 2018. Also Stockhouse.com published the news titled: “MorphoSys to Present at Upcoming Investor Conferences” on August 21, 2018. Stockhouse.com‘s news article titled: “MorphoSys AG To Be Listed In MDAX” with publication date: September 06, 2018 was also an interesting one.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.